4 Biotech Stocks That Doubled in 2025: Will They Sustain Momentum in 2026?

lunes, 22 de diciembre de 2025, 11:17 am ET1 min de lectura
IONS--
KOD--
MNPR--

Ionis Pharmaceuticals (IONS), Structure Therapeutics (GPCR), Monopar Therapeutics (MNPR), and Kodiak Sciences (KOD) have provided more than double returns in 2025. The biotech sector regained momentum in the latter part of 2025 due to improved policy clarity, a rebound in mergers and acquisitions, and healthy fundamentals. Looking forward to 2026, investors will focus on clinical execution, regulatory milestones, commercialization progress, and potential strategic transactions.

4 Biotech Stocks That Doubled in 2025: Will They Sustain Momentum in 2026?

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios